glp-1 risks GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists Unlocking the broad health benefits
Description
Background Type 2 diabetes mellitus (T2DM) is a chronic condition that affects millions of patients worldwide, posing significant challenges to both patients and healthcare systems
Dopamine therapies have not been shown to prevent disease progression
The FDA approved types of GPL-1 diabetes treatments for weight loss including versions of Mounjaro and Ozempic
[DOI] [PMC free article] [PubMed] [Google Scholar] 122
